A2.21 The increase of circulating CD4+ T-cells with effector phenotype in patients with systemic lupus erythematosus may be reverted after belimumab therapy
A2.21 The increase of circulating CD4+ T-cells with effector phenotype in patients with systemic lupus erythematosus may be reverted after belimumab therapy